Manages acute pain severe enough to require an opioid analgesic. ANDA 210175, held by Ascent Pharms Inc. Oxymorphone Hydrochloride.
As of Nov 16, 2026, ANDA 210175 (Oxymorphone Hydrochloride), held by Ascent Pharms Inc, was first approved by FDA on Feb 2, 2018, with 8 approved supplements and 0 published complete response letters.
Oxymorphone hydrochloride tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration, and persist over the course of therapy, reserve opioid analgesics, including oxymorphone hydrochloride tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 2, 2018 | Original application | Approved |
| Oxymorphone Hydrochloride5MG · tablet;oral | Oxymorphone Hydrochloride | Rx |
| Oxymorphone Hydrochloride10MG · tablet;oral | Oxymorphone Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 10REMS | Approved | None posted |
| Dec 22, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 7REMS | Approved | None posted |
| Dec 15, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 4, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 8, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 2REMS | Approved | None posted |
| Feb 2, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters